1-3 of 3
Gilles Thibault, PharmD
Close
Sort by
Journal Articles

Cleavage of Anti-PF4/H IgG Antibodies By Ides, and Potential Benefit in the Treatment of Heparin-Induced Thrombocytopenia

Claire Kizlik-Masson, Quentin Deveuve, Yuhang Zhou, MD PhD, Caroline Vayne, PharmD, Gilles Thibault, PharmD, PhD, Steven Edward McKenzie, MD PhD, Claire Pouplard, PharmD, PhD, Stéphane Loyau, Jérôme Rollin, PhD, Yves Gruel, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 518.
https://doi.org/10.1182/blood-2018-99-114450
Published: 2018
Journal Articles

Influence of FcγRIIA H131R Polymorphism on the Risk of Thrombosis in HIT and Variable Effect of Normal IgG on Platelet Activation

Jerôme Rollin, PhD, Claire Pouplard, Dorothee Leroux, Armand Saada, Céline Behier, Valérie Gouilleux Gruart, Gilles Thibault, PharmD, Yves Gruel, MD PhD
Journal: Blood
Blood (2014) 124 (21): 234.
https://doi.org/10.1182/blood.V124.21.234.234
Published: 2014
Journal Articles

Long-Term Effects of In Vivo Administration of An Anti-VLA-4 Antibody (natalizumab) on Mobilization of Committed and Primitive Hematopoietic Progenitor Cells In Humans

Jorge Domenech, MD, PhD, Julien Goustille, PharmD, Maud Pallix, MD, Zakia Bekhechi, PharmD, Elfi Ducrocq, Michel Degenne, PharmD, Olivier Herault, MD, PhD, Gilles Thibault, PharmD, Anne-Marie Guennoc, MD, Christian Binet, MD
Journal: Blood
Blood (2010) 116 (21): 2264.
https://doi.org/10.1182/blood.V116.21.2264.2264
Published: 2010